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The sequential doxorubicin-CMF (CMF¼cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to
CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-
positive patients were randomised to: (a) CMF 6 cycles (CMF); (b) doxorubicin 4 cycles followed by CMF 6 cycles (A-CMF);
(c) CMF 6 cycles followed by goserelin plus tamoxifen 2 years (CMF-GT); and (d) doxorubicin 4 cycles followed by CMF 6
cycles followed by goserelin plus tamoxifen 2 years (A-CMF-GT). The study used a 2 2 factorial experimental design to
assess: (1) the effect of the chemotherapy regimens (CMF vs A-CMF or arms aþc vs bþd) and (2) the effect of adding GT after
chemotherapy (arms aþb vs cþd). At a median follow-up of 72 months, A-CMF as compared to CMF significantly improved
disease-free survival (DFS) with a multivariate hazard ratio (HR)¼0.740 (95% confidence interval (CI): 0.556–0.986; P¼0.040) and
produced a nonsignificant improvement of overall survival (OS) (HR¼0.764; 95% CI: 0.489–1.193). The addition of GT after
chemotherapy significantly improved DFS (HR¼0.74; 95% CI: 0.555–0.987; P¼0.040), with a nonsignificant improvement of OS
(HR¼0.84; 95% CI: 0.54–1.32). A-CMF is superior to CMF. Adding GT after chemotherapy is beneficial for premenopausal node-
positive patients.
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Adjuvant therapy of breast cancer is one of the most successful
treatment strategies in oncology. Hundreds of randomised clinical
trials of adjuvant therapy conducted worldwide have demonstrated
the efficacy of many therapeutic options, both hormonal and
cytotoxic. Not all data coincide, which makes it difficult to select
the best adjuvant combination for each patient. In an attempt to
elucidate controversial issues, the Early Breast Cancer Trialists’
Collaborative Group (EBCTCG) (1996, 1998a,b) periodically
reviews the randomised evidence. However, the last update of
the meta-analysis leaves several important questions unanswered
(2000a,b).
First, anthracycline-based polychemotherapy is, on average,
more effective than CMF-like (CMF¼cyclophosphamide, metho-
trexate, fluorouracil) regimens, producing a further 15% reduction
in the annual odds of death. However, uncertainty remains as to
what is the optimal anthracycline-based regimen. Different
anthracycline-based regimens have become standard in Europe,
the USA and Canada. However, for some of these regimens, there
is no clear proof of superiority over the CMF. For instance, a
sequential regimen consisting of four courses of doxorubicin
followed by various courses of CMF has gained widespread
acceptance as a standard regimen in Europe. This was fuelled by
the results of a randomised trial by Bonadonna et al (Buzzoni et al,
1991; Bonadonna et al, 1995), in which this sequential regimen
compared favourably with a regimen alternating doxorubicin and
CMF courses. However, the superiority of the Bonadonna regimen
over the classical CMF regimen has never been demonstrated.
Second, the optimal use of hormonal therapy in premenopausal
women remains one of the most controversial issues. For this
group of patients, ovarian ablation and tamoxifen are both
effective adjuvant therapies (EBCTCG 1996,1998a,b,2000a,b).
However, it is unclear as to whether ovarian suppression is
beneficial after chemotherapy, and whether the combination of
tamoxifen plus ovarian suppression is more effective than either
treatment alone, particularly in patients who also receive
chemotherapy.
In 1991, the Gruppo Oncologico Centro-Sud-Isole (GOCSI), an
Italian Cooperative Group, started a randomised clinical trial of
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sadjuvant therapy for premenopausal early breast cancer patients.
The trial, labelled MAM1, was designed with a factorial scheme (1)
to compare the efficacy of a sequential doxorubicin-CMF
regimen vs CMF and (2) to evaluate the benefit of adding
tamoxifen plus ovarian suppression obtained with goserelin after
chemotherapy. Here, we report the results of the MAM1 trial after
a median follow-up of 6 years.
PATIENTS AND METHODS
This trial was open for patient accrual between September 1991
and December 1996. Its objective was to treat premenopausal
women affected by primary adenocarcinoma of the breast with
axillary lymph nodes involvement and no distant metastases (T0–
T3, N1/2, M0). Premenopausal status was indicated by the regular
occurrence of menses at the time of the randomisation. A
premenopausal hormonal profile was required for patients with
up to 6 months of amenorrhoea and for patients who had
previously undergone hysterectomy for benign disease.
Primary therapy consisted of removal of the entire cancer by a
segmental mastectomy (quadrantectomy) plus axillary dissection
or a modified radical mastectomy with no gross or microscopic
invasive tumour at the resection margin. Required laboratory data
were limited to an initial bilirubin level within 1.5 times the
institutional upper normal limit (UNL): AST p2.0 UNL,
creatinine level p1.5 UNL and, before each cycle of chemother-
apy (including the first), leucocytes count X4000ml
 1 and platelet
count X100000ml
 1. Eligible patients also had pretreatment chest
radiographs, bone scan, liver ultrasounds and ECGs. Steroid
receptor analysis was carried out by immunohistochemistry with a
cutoff of 10% of cells with specific staining. All patients provided
written informed consent meeting all national and institutional
guidelines.
Treatment was delivered on an outpatient basis, starting within
6 weeks from primary surgery.
Randomisation was performed centrally at the GOCSI Data
Operations unit located in Naples, Italy, upon fax request and
verification of selection criteria by the central data manager.
Allocation was performed by computerised minimisation proce-
dure. After balancing for centre and lymph node involvement (1–3
vs X4 nodal metastases), patients were allocated to one of four
treatment arms:
(a) CMF 6 cycles (CMF).
(b) Doxorubicin 4 cycles followed by CMF 6 cycles (A-
CMF).
(c) CMF 6 cycles followed by goserelin plus tamoxifen  2 years
(CMF-GT).
(d) Doxorubicin 4 cycles followed by CMF 6 cycles followed
by goserelin plus tamoxifen  2 years (A-CMF-GT).
The study used a 2 2 factorial experimental design to assess
the following two ‘factors’: (1) the effect of the chemotherapy
regimens (CMF vs A-CMF or arms aþc vs bþd) and (2) the
effect of adding GT upon completion of chemotherapy (arms aþb
vs cþd).
Irrespective of study arm: doxorubicin was given at 75mgm
 2
every 3 weeks; CMF consisted of cyclophosphamide
100mgm
 2 o.s. on days 1–14, methotrexate 40mgm
 2 and
fluorouracil 600mgm
 2 both given intravenously (i.v.) on days 1
and 8 every 4 weeks; goserelin was given by subcutaneous implant
of 3.6mg every 4 weeks for 2 years (26 administrations); and
tamoxifen was given per o.s. at 20mg q.d. for 2 years.
Complete blood cell counts were obtained before each
chemotherapy treatment. If the WBC count was less than
4000ml
 1 or the platelet count less than 100000ml
 1 on day 1,
chemotherapy was delayed. If after a 1-week delay these minimal
levels were not achieved, dose was reduced by 25% decrements
according to a prespecified scheme based on the degree of toxicity.
If haematologic toxicity was present on day 8 of CMF, the dose was
reduced without treatment delay.
Radiation therapy, when used, was given after completion of
chemotherapy. Although recommendations regarding this techni-
que were included in the written protocol, investigators were
permitted to follow institutional guidelines.
All patients were evaluated every 3 months during years 1–3,
twice annually for the next 3 years and annually thereafter. A chest
X-ray and a liver ultrasound were obtained at entry, every 6
months during years 1–6 and annually thereafter. A bone scan and
a mammogram were required before treatment was started, then
annually during years 1–6 and every 2 years thereafter.
Disease-free survival (DFS), which was the primary study end
point, was measured from study entry until local recurrence,
distant relapse, contralateral breast cancer or death without
relapse, whichever occurred first. Surviving patients who were
disease free were censored at the date on which they were last
known to be free from their primary breast cancer. The secondary
end point of overall survival (OS) was measured from study entry
until death from any cause; surviving patients were censored at the
date of last contact.
Target accrual was 940 patients over 36 months, with the data
being analysed 3 years after completion of accrual. This provided
80% power to detect an 8% absolute difference in event rate for
either main effect, assuming an event rate equal to 70% in the
control groups. The trial was not dimensioned to look for
interactions between the two main factors. Kaplan–Meier curves
with log-rank tests were used to compare the distribution of time
with events. Cox’s proportional hazards regressions with Wald’s w
2
tests were used to model and assess the relation between DFS and
OS with treatment factors, adjusting for clinical variables. The
interaction between factors was assessed by the likelihood ratio
test. Disease-free survival and OS analyses are on an intention-to-
treat basis. All P-values are two-sided.
Toxicity grading used the NCI common toxicity criteria. Patient
information was collected on standard study forms by the GOCSI
Data Operations unit located in Naples, Italy, and entered into the
GOCSI database. Data were current as of May 2002.
RESULTS
Between September 1991 and December 1996, 466 volunteer female
patients were accrued by 19 Italian centres. This total was about
half of that planned (940); however, the trial was closed for a
slower-than-expected accrual rate. The complete patient flow
according to the Consort requirements is reported in Figure 1. The
overall compliance to the treatment was 95% for chemotherapy
and 70% for endocrine therapy (Figure 1). The main character-
istics of this patient population are reported in Table 1. The
median patient age was 44 years, 79% had oestrogen receptor
(ER)-positive or -unknown tumours, the median number of
involved lymph nodes was 3 and 44% had four or more affected
axillary lymph nodes. The regimens were balanced with regard to
these and all other major pretreatment variables. After a median
follow-up of 72 months, there were 194 relapses and 82 deaths
recorded.
First comparison: A-CMF vs CMF
At univariate analysis, DFS was significantly prolonged for the
sequential anthracycline-based regimen (arms bþd) compared
with the CMF regimen (arms aþc) (Figure 2). The estimated DFS
at 5 years were 65% for the sequential treatment and 54% for CMF
(P¼0.044). This effect remained statistically significant at multi-
variate analysis even after adjusting for the number of positive
nodes (1–3 vs X4), tumour size (p2 vs 42cm), age (p35 vs
Doxorubicin followed by CMF vs CMF
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s435) and tumour ER status and stratifying based on the GT
treatment with a hazard ratio (HR)¼0.740 (95% confidence
interval (CI): 0.556–0.986; P¼0.040).
The estimated OS at 5 years were 83% for A-CMF vs 79% for
CMF. The difference was not significant at univariate log-rank test
(P¼0.26) or at Cox’s multivariate analysis (HR¼0.764; 95% CI:
0.489–1.193).
Second comparison: chemo-GT vs chemo
At univariate analysis, DFS was significantly improved by the
addition of GT after chemotherapy (arms cþd) compared with
chemotherapy alone (arms aþb) (Figure 3). The estimated
probability of being disease free at 5 years was 64% for
chemo-GT and 53% for chemotherapy alone (P¼0.044)
(Figure 3). The benefits of adding GT remained statistically
significant at multivariate analysis even after adjusting for the
number of positive nodes, tumour size, age and tumour ER status
and stratifying by type of chemotherapy (A-CMF vs CMF) with a
HR¼0.740 (95% CI: 0.555–0.987; P¼0.040). As expected, there
was a trend toward a greater efficacy of the GT treatment in the
ER-positive/ER-unknown subgroup of patients as compared with
the ER-negative patients (HR: 0.73 vs 0.89, respectively). However,
probably due to the low statistical power of the test, the interaction
between GT effect and ER status was not statistically significant.
The estimated OS at 5 years were 82% for chemo-GT vs 80%
for chemotherapy alone. The difference did not reach statistical
significance at univariate log-rank test (P¼0.48) or at Cox’s
multivariate analysis (HR¼0.84; 95% CI: 0.54–1.32).
Interaction between factors
This study was not designed for formal comparisons among single
arms, nor for analysis of the interaction between factors. Never-
theless, for description purposes this analysis is reported. Kaplan–
Meier estimates of DFS at 5 years were 0.51 for CMF, 0.56 for
CMF-GT, 0.53 for A-CMF and 0.71 for A-CMF-GT. At
multivariate analysis, HR was 0.86 for CMF-GT, 0.86 for A-
CMF and 0.53 for A-CMF-GT as compared to the reference
CMF arm. Although a lower HR was evident for the arm in which
both factors (sequential anthracycline and GT) were associated,
there was no statistical significant interaction between the two
factors (likelihood ratio test P¼0.55).
Toxicity
The incidence of standard toxicity data for grades 3 to 4 during
chemotherapy administration is reported in Table 2 on a per
patient basis. There were no treatment-related deaths during
chemotherapy. There was only one death within the first 6 months
CMF CMF-GT A-CMF A-CMF-GT
CMF CMF-GT A-CMF A-CMF-GT
CMF CMF-GT A-CMF A-CMF-GT
Allocated to intervention 114 120 119 113
Received allocated intervention  109 116 112 105
Did not receive allocated intervention 
Chemo  54 8 8
Endocrine  03 4 0 3 6
Follow-up data: 
Recorded deaths 21  19  21  14 
Pts. with less than 3 years of follow-up  27  41  26  21 
Pts. with 3−5 years of follow-up  22  17  25  16 
Pts. with more than 5 years of follow-up  38  38  39  54 
Discontinued intervention  6  5  8  8 
Lost to follow-up  2  2  1  0 
Unacceptable toxicity  1  1  2  1 
Disease recurrence  1  1  2  3 
Consent withdrawal  2  1  3  3 
Death 0 0 01
Analysed 120  119  113 
Randomised: 466
114 
Figure 1 Complete patient flow according to the Consort requirements.
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sof protocol treatment; the cause of death, cerebral infarction, was
considered unrelated to treatment. As expected, a higher incidence
of grade 3–4 alopecia was seen for the A-CMF regimen (30 vs
1.7%; Po0.0001). Grade 3 or greater emesis was significantly more
common for the anthracycline-containing regimen (8.2 vs 3.8%;
P¼0.048). Incidence of other adverse events was well balanced
across arms.
The number of cycle delays was relatively small, thus accounting
for a delivered dose intensity of more than 90% of the planned
one, in each arm. Dose reductions were also infrequent with
a total delivered dose of more than 95% of the planned one, in
each arm.
DISCUSSION
Our current understanding of the adjuvant treatment of breast
cancer is based on more than 25 years of randomised trials.
Interpretation of such an amount of data is not always
straightforward and represents a challenging task for the scientific
Table 1 Main pretreatment characteristics
CMF CMF-GT A-CMF A-CMF-GT
No. of patients 114 120 119 113
Tumour size
Median (cm) 2 2.2 2.5 2.5
Range (cm) 0.5–10 1–8 0.18–20 0.7–9.5
Age (years)
Median 45 44 43 44
Range 29–52 28–51 20–51 25–50
ER receptor
Positive 49 43% 41 34% 37 31% 48 42%
Negative 30 26% 27 23% 24 20% 15 13%
Unknown 35 31% 52 43% 58 49% 50 44%
PgR receptor
Positive 41 36% 37 31% 35 29% 41 36%
Negative 33 29% 24 20% 20 17% 19 17%
Unknown 40 35% 59 49% 64 54% 53 47%
Node metastases
1–3 64 56% 64 53% 64 54% 61 54%
4+ 50 44% 56 46% 55 46% 52 46%
Grading
1 3 3% 3 3% 4 3% 1 1%
2 27 24% 24 20% 30 25% 23 20%
3 44 39% 50 42% 43 36% 50 44%
Unknown 40 35% 43 36% 42 35% 39 35%
CMF¼CMF 6 cycles; CMF-GT¼CMF 6 cycles followed by goserelin plus tamoxifen 2 years; A-CMF¼doxorubicin 4 cycles followed by CMF 6 cycles; A-
CMF-GT¼doxorubicin 4 cycles followed by CMF 6 cycles followed by goserelin plus tamoxifen 2 years; ER receptor¼oestrogen receptor; PgR receptor¼progester-
progesterone receptor; CMF¼cyclophosphamide, methotrexate, fluorouracil.
P = 0.044 
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Figure 2 Disease-free survival curve by type of chemotherapy.
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Figure 3 Disease-free survival curve in the presence of GT.
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scommunity. A formidable help in addressing controversial issues
comes from the periodical meta-analysis of all randomised trials
worldwide by the EBCTCG. Nonetheless, after its last update, a
good deal of uncertainty remains as to what is the optimal
anthracycline-based regimen and which is the best adjuvant
strategy in premenopausal women with endocrine-responsive
tumours. The MAM1 trial reported here attempts to answer two
main questions that may contribute to elucidate both areas of
controversy. As a general limitation, the trial is penalised by a half-
than-expected accrual that have greatly reduced its statistical
power. It may be argued that this decreases the value of the trial
results. However, underpowered trials have by definition a high
chance of not detecting a statistically significant difference between
treatments (i.e. high chance of being false-negative trials). On the
contrary, once a statistically significant difference is detected, as in
the case of the MAM1 trial, the small sample size does not increase
the risk that such a difference be a spurious result (i.e. a false-
positive), although it affects the precision of the point estimate for
the HR.
The EBCTCG overview results, published in 1998 (1998a) and
updated in September 2000 (2000a), have definitely shown that
anthracycline-based CT yields superior results in terms of
recurrence and mortality rates when compared with CMF.
However, diverse polychemotherapy regimens containing an
anthracycline are currently used in clinical practice and there is
no universally accepted standard regimen (Wood et al, 1994;
Budman et al, 1998; Mouridsen, 1999, 2000; Piccart et al, 2001;
Cardoso et al, 2002; Fumoleau et al, 2003). In the absence of direct
comparisons between currently used anthracycline-based regi-
mens, the definition of standard regimen should be based on a
demonstrated superiority over the CMF.
In 1991, the Milan group (Buzzoni et al, 1991) published the
first report of a randomised trial evaluating a sequential regimen
based on doxorubicin followed by CMF, which was compared
with a regimen alternating two cycles of CMF and one cycle
of doxorubicin. The sequential therapy arm was superior, and
at 5 years, the DFS rate was 61% for 179 patients with an average of
nine involved lymph nodes. The results have been confirmed at
10-year follow-up (Bonadonna et al, 1995). This trial was designed
to compare two different schedules of administration of the
same drugs, based on theoretical considerations and mathematical
modelling, and lacked of a standard control arm (i.e. a simple
CMF arm). Nonetheless, the reported 5-year DFS for the
sequential arm was judged by many in Europe as an indirect
proof of the superiority of this regimen over the classical CMF,
thus causing its rapid acceptance as standard treatment for node-
positive patients. It was also argued that this sequential
doxorubicin–CMF regimen should be the preferred way of
incorporating the anthracycline in an adjuvant regimen. Indeed,
according to the Norton–Simon model and based on the
apparently excellent DFS in the Bonadonna trial, many oncologists
have deemed the sequential regimen superior to those regimen in
which the anthracycline was replacing a CMF drug (i.e. FAC/CAF
(cyclophosphamide, doxorubicin, 5-fluorouracil) regimens). At
that time, the MAM1 trial was promptly designed to evaluate
directly, with one of its two factorial comparisons, the superiority
of this sequential regimen over the classical CMF and it represents
to date the only full report addressing this issue. Owing to its
inherent design, with an imbalanced number of chemotherapy
cycles between arms (six for CMF and 10 for ACMF), our trial
cannot clarify whether the observed DFS improvement is related to
the introduction of the anthracycline or to the longer chemother-
apy administration in the sequential arms. Nonetheless, our results
demonstrate the superiority of the sequential regimen, therefore
providing experimental support to the conviction that such a
regimen should be deemed as a standard anthracycline-based
regimen. Also, it confirms a fair toxicity profile for this regimen,
with a very manageable incidence of grade 3–4 adverse
events. Given this very low toxicity profile, it may be questioned
that some under-reporting may have occurred. However, the
high average relative dose intensity and the high delivered total
dose confirm that the regimen was well tolerated. Furthermore,
both toxicity rates and delivered dose and dose intensity are
consistent with what is already reported for the same regimen
(Buzzoni et al, 1991).
The finding of our trial is corroborated by the pooled analysis of
two large randomised studies comparing a similar sequential
regimen, with epirubicin in substitution of doxorubicin, against
CMF, very recently reported in abstract form (Poole et al, 2003).
Consistently with the results of our trial, the combined analysis
demonstrated a benefit for the sequential regimen in both relapse-
free survival (HR¼0.70; P¼0.0003) and OS (HR¼0.64;
P¼0.0001). With regard to the hypothesised superiority of the
sequential regimen as compared to the FAC/CAF regimens, neither
our trial nor the above-cited pooled analysis is designed to give
information about this topic. However, a recent trial directly
addressing the issue of the scheduling (sequential vs concurrent)
failed to show any difference between these two treatment
Table 2 Incidence of grade 3–4 toxic events by study arm on a per patient basis
CMF CMF-GT A-CMF A-CMF-GT
Patients 114 120 119 113
Alopecia 1 0.9% 3 2.5% 28 23.5% 42 37.2%
Astenia 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Cystitis 0 0.0% 0 0.0% 1 0.8% 0 0.0%
Dermatologic 1 0.9% 1 0.8% 0 0.0% 0 0.0%
Diarrhoea 1 0.9% 0 0.0% 1 0.8% 1 0.9%
Fever 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Gastrointestinal 2 1.8% 0 0.0% 1 0.8% 1 0.9%
Liver 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Mucositis 0 0.0% 1 0.8% 0 0.0% 0 0.0%
Vomiting 4 3.5% 5 4.2% 10 8.4% 9 8.0%
Others 0 0.0% 1 0.8% 0 0.0% 0 0.0%
Anaemia 1 0.9% 0 0.0% 1 0.8% 0 0.0%
Leuco/neutropenia 5 4.4% 4 3.3% 5 4.2% 5 4.4%
Piastrinopenia 0 0.0% 0 0.0% 1 0.8% 0 0.0%
CMF¼CMF 6 cycles; CMF-GT¼CMF 6 cycles followed by goserelin plus tamoxifen 2 years; A-CMF¼doxorubicin 4 cycles followed by CMF 6 cycles; A-
CMF-GT¼ doxorubicin 4 cycles followed by CMF 6 cycles followed by goserelin plus tamoxifen 2 years; CMF¼cyclophosphamide, methotrexate, fluorouracil.
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sschedules (Citron et al, 2003), and thus the present evidence does
not support the preferential use of sequential schedules.
Not all the other adjuvant anthracycline-based regimen used
worldwide have equally demonstrated their superiority vs the CMF.
In the last published EBCTCG meta-analysis (1998a), the
advantage of anthracycline-based CT was found almost exclusively
when a three-drug regimen was used (either CEF (cyclopho-
sphamide, epidoxorubicin, fluorouracil) or CAF. Since the 1998
Oxford publication, four more large trials have been reported. Two
of these trials tested a three-drug regimen and two a two-drug
regimen. In the Intergroup Study 0102, six cycles of CAF were
superior to six cycles of CMF in 2691 high-risk node-negative
breast cancer patients (Hutchins et al, 1998). In the Danish–
Swedish Breast Cancer Cooperative Group randomised 1195 breast
cancer patients, nine cycles of CEF resulted in better 6-year
survival in some patient subsets as compared to nine cycles of
CMF, given only on day 1 of a three-weekly cycle (Mouridsen et al,
1999). However, in this trial, the ‘monodose’ CMF could be
considered a suboptimal control. In a Belgian study (Piccart et al,
2001), no difference emerged between CMF and full dose EC with
50 months of median follow-up. Similarly, in the NSABP B-23 trial,
no differences were found between four cycles of a two-drug
regimen (AC) and six cycles of CMF in 2008 node-negative, ER-
negative patients (Fisher et al, 2001).
Summing up the current evidence, it appears that only two class
of anthracycline-based regimens have provided sufficient indica-
tion of their superiority over CMF: those with three drugs (FAC or
FEC like) and the sequential anthracycline-CMF regimens (like
the one that we used in the MAM1 trial), while for two-drug
regimens, they rather seem equivalent to CMF. This should be
adequately considered both in the clinical practice and in the
research setting. In particular, at this latter regard, the interpreta-
tion of the results of taxane-based adjuvant regimens should
carefully consider the type of anthracycline-based regimen
employed as a reference arm.
The optimisation of the adjuvant strategy in premenopausal
women with endocrine-responsive disease represents a very
intriguing task owing to the availability of various alternative
and potentially complementary therapeutic options, including
chemotherapy, tamoxifen and ovarian suppression. Indirect
comparisons within EBCCTG overview (1996; 2000b) suggest a
similar benefit in terms of the reduction of recurrence and death
risk, form adjuvant ovarian ablation (by surgical oophorectomy or
ovarian irradiation), chemotherapy or, for ERþ patients, from
tamoxifen. Direct comparisons within the meta-analysis also
indicate that the effect of chemotherapy is independent of (and
additive with) the effect of tamoxifen, in women aged p50 or 450
years, thus suggesting that the administration of chemotherapy
and tamoxifen should be the standard treatment for the majority of
women with endocrine-responsive tumours. More controversial
remains the role of ovarian ablation. Recently, the results of five
comparative trials of adjuvant hormonal therapy using GnRH
agonists alone (Schmid et al, 2002; Kaufmann et al, 2003) or in
combination with tamoxifen (Boccardo et al, 2000; Roche et al,
2000; Jakesz et al, 2001), vs cytotoxic chemotherapy have shown at
least equivalence of effect in premenopausal women with ER-
positive tumours; therefore, the ovarian suppression may repre-
sent a valid alternative to chemotherapy at least for patients with
low–moderate risk. The main question now is whether there is an
additional benefit from adding the suppression of ovarian
function, either alone or in combination with tamoxifen, to
patients who also receive chemotherapy. In the MAM1 trial
presented here, we show how the addition of a combination of
goserelin plus tamoxifen for 2 years after chemotherapy, for ER-
unselected premenopausal patients, yields a further statistically
significant reduction in the hazard of relapse (HR¼0.74). Also, a
trend to a reduction in the hazard of death was observed
(HR¼0.84), although nonstatistically significant. The effect
appears unrelated to the type of chemotherapy (A-CMF or
CMF) administered, as no interaction was observed between the
two factors of the study design. With regard to the endocrine
treatment, however, some limitations of our trial deserve discus-
sion. First, about 21% of patients were ER negative and as much as
42% had unknown ER status. Second, about 30% of patients
randomised to goserelin plus tamoxifen did not complete the
endocrine therapy as per protocol (Figure 1). Both these issues
may have reduced the magnitude of the benefit from the endocrine
treatment. Third, a small, and nonstatistically significant, imbal-
ance in the distribution of ER-negative patients, which appear
more frequent in the chemotherapy-only arms (Table 1), may have
favoured the endocrine treatment. However, this should be a
minor issue since the benefits of the endocrine treatment persist at
multivariate analysis, where adjustment by receptor status along
with other major prognosticators was carried out. Fourth, in our
study, tamoxifen was administered for 2 years only, while the
optimal duration of such a treatment is now known to be 5 years.
Finally, the incidence of chemotherapy-induced amenorrhoea was
not recorded in our study and this did not allow testing for an
interaction between the persistence of menses and the effect of
goserelin plus tamoxifen.
Results similar to ours have already been reported by others in a
preliminary manner. The Zoladex In Premenopausal Patients
(ZIPP) trial determined the effect of adding goserelin to standard
adjuvant treatment (surgery7radiotherapy7chemotherapy7
tamoxifen) in women o50 years of age. At a median follow-up
of 66 months, the addition of goserelin reduced both the hazard of
recurrence (HR¼0.80; 95% CI: 0.7–0.92; Po0.001) and death
(HR¼0.82; 95% CI: 0.67–0.99; P¼0.04). Subgroup analysis
suggested that goserelin had its greatest effect in patients with
ER-positive tumours who did not receive chemotherapy, but none
of the tests for interaction were significant (Baum et al, 2001). A
study (INT-0101) by the Easter Cooperative Oncology Group
(ECOG)/South West Oncology Group (SWOG)/CALGB (Cancer
and Leukaemia Group B) (Davidson et al, 1999) in node-positive,
ER-positive patients compared the addition of goserelin with or
without tamoxifen to CAF. At a median follow-up of 6.2 years,
there was a trend in favour of improved DFS for the addition of
goserelin to CAF, although this just failed to reach statistical
significance. The addition of goserelin plus tamoxifen to CAF
chemotherapy resulted in a significant benefit in DFS over the use
of CAF plus goserelin (Po0.01). In this study, the addition of
tamoxifen seemed to be more efficacious in those women with
postmenopausal oestradiol (E2 )levels at the end of adjuvant CAF
therapy, while goserelin was more beneficial in women with
premenopausal oestradiol levels at the end of CAF therapy.
In summary, the results of our trial and of INT-0101 trial
indicate an additional benefit from adding goserelin plus
tamoxifen after chemotherapy, for moderate-to-high-risk
(nodeþ) patients. Similarly, according to the ZIPP trial, the
addition of goserelin alone may yield an additional benefit as
compared to chemotherapy alone. However, there are no data
evaluating the worth of inducing ovarian suppression to patients
who also receive tamoxifen after chemotherapy and this question
remains a matter of research.
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